Evidence map›Paper›PMID 41568670›Full record

Observational studyAnnals of clinical and translational neurology2026

Remote Assessment of Ataxia Severity in SCA3 Across Multiple Centers and Time Points.

Marcus Grobe-Einsler, Vivian Maas, Arian Taheri Amin, Jennifer Faber, Tamara Schaprian, Katharina Hill, Matthis Synofzik, Lisa H Graf, Heike Jacobi, Manuela Lima and 11 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Marcus Grobe-EinslerGerman Center for Neurodgenerative Diseases (DZNE), Bonn, Germany.ORCID https://orcid.org/0000-0002-1808-2134
Vivian MaasGerman Center for Neurodgenerative Diseases (DZNE), Bonn, Germany.
Arian Taheri AminGerman Center for Neurodgenerative Diseases (DZNE), Bonn, Germany.
Jennifer FaberGerman Center for Neurodgenerative Diseases (DZNE), Bonn, Germany.
Tamara SchaprianGerman Center for Neurodgenerative Diseases (DZNE), Bonn, Germany.
Katharina HillGerman Center for Neurodgenerative Diseases (DZNE), Bonn, Germany.
Matthis SynofzikCenter for Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.ORCID https://orcid.org/0000-0002-2280-7273
Lisa H GrafCenter for Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
Heike JacobiDepartment of Neurology, University Hospital Heidelberg, Heidelberg, Germany.ORCID https://orcid.org/0000-0002-6986-3969
Manuela LimaFaculdade de Ciências e Tecnologia, Universidade dos Açores, Ponta Delgada, Portugal.
Ana F FerreiraFaculdade de Ciências e Tecnologia, Universidade dos Açores, Ponta Delgada, Portugal.
Bart P van de WarrenburgRadboud University Medical Center, Department of Neurology, Nijmegen, the Netherlands.
Ilse H J WillemseRadboud University Medical Center, Department of Neurology, Nijmegen, the Netherlands.
Dagmar TimmannDepartment of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Essen University Hospital, University of Duisburg-Essen, Essen, Germany.
Andreas ThiemeDepartment of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Essen University Hospital, University of Duisburg-Essen, Essen, Germany.
Paola GiuntiAtaxia Centre, Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK.
Hector Garcia-MorenoAtaxia Centre, Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK.
Magda M SantanaCenter for Neuroscience and Cell Biology, University of Coimbra (CNC-UC), Coimbra, Portugal.
Jeannette Hübener-SchmidInstitute for Medical Genetics and Applied Genomics, University of Tuebingen, Tuebingen, Germany.ORCID https://orcid.org/0000-0002-4973-0923
Elin H DaviesAparito - a Wholly Owned Subsidiary of Eli Lilly and Company, Wrexham, UK.
Thomas KlockgetherGerman Center for Neurodgenerative Diseases (DZNE), Bonn, Germany.

Funding

Ataxia UKBundesministerium für Bildung und ForschungGerman Academic Exchange ServiceGerman Federal Ministry of Education and ResearchMedical Research CouncilNational Ataxia FoundationUniversity College London
6 · The paper itself

Abstract

objectiveSpinocerebellar ataxia type 3 (SCA3) is a genetically defined ataxia. The Scale for Assessment and Rating of Ataxia (SARA) is a clinician-reported outcome that measures ataxia severity at a single time point. In its standard application, SARA fails to capture short-term fluctuations, limiting its sensitivity in trials. To overcome this, we employed SARA

methodsWe assessed feasibility and validity of SARA

resultsAdherence to the study protocol was generally high (80.2%) with valid scores in 79.2% of 1459 recordings. Maximum adherence occurred over a 4-day period (84.8%). Fluctuations ranged 3.0 points between lowest and highest scores (IQR: 2.5-4.5) and 1.0 point based on score IQRs (IQR: 0.5-1.5), corresponding to 10.7% and 3.6% of the maximal SARA

interpretationSARA

Indexed as

Machado-Joseph DiseaseSeverity of Illness IndexAdultAgedFeasibility StudiesFemaleHumansLongitudinal StudiesMaleMiddle AgedMobile ApplicationsRemote Patient MonitoringataxiafluctuationremoteSARAhomeSCA

Identifiers

PMID41568670
PMCPMC13358552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.